Safety and efficacy of HepaSphere 50–100 μm in the treatment of hepatocellular carcinoma

Zurstrassen, Charles Edouard; Gireli, Luiz Paulo De Oliveira; Tyng, Chiang Jeng; Bitencourt, Almir Galvão Vieira; Guimarães, Marcos Duarte; Barbosa, Paula Nicole Vieira Pinto; Cavalcante, Aline C B S; Matushita, João Paulo Kawaoka; Amoedo, Maurício Kauark; Coimbra, Felipe José Fernández; Alves, Rogério Camargo Pinheiro; Chojniak, Rubens

doi:10.1080/13645706.2017.1288142

Cited by 7 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another prospective cohort study illustrates that in 18 HCC patients treated with DEB-TACE, the application of 50-100 lm HepaSpheres achieves an ORR of 53.3%, and the BCLC stage is correlated with treatment response rate (Zurstrassen et al, 2017). In regard to the CalliSpheres, a cohort study illuminates that in 50 middle stage HCC patients treated with DEB-TACE using CalliSpheres, CR, PR, SD, and PD are 35.4%, 29.4%, 17.6%, and 17.6%, respectively, in patients treated with 100-300 lm beads, and are 33.1%, 23.1%, 20.8%, as well as 23.0% respectively in patients treated with 300-500 lm beads .…”

Section: Discussionmentioning

confidence: 99%

“…HepaSpheres and CalliSpheres are two competitive microsphere products in the treatment using DEB-TACE among HCC patients. HepaSpheres has been applied in the clinical practice for almost 30 years, it is a vinyl alcohol-sodium acrylate microsphere featured by good quality in chemotherapeutic absorbing/releasing abilities and its acceptable flexibility in the vessels (Jordan et al, 2010;Zurstrassen et al, 2017). As for CalliSpheres, it is the first microsphere product completely produced in China and utilized for DEB-TACE in recent years, and there are many clinical studies and trials elucidating that it presents with satisfying efficacy and safety in DEB-TACE treatments for HCC patients (Ren et al, 2019;Duan et al, 2020;Liang et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients

et al. 2021

View full text Add to dashboard Cite

This study aimed to compare efficacy and safety of HepaSpheres and CalliSpheres in unresectable large hepatocellular carcinoma (HCC) patients. One hundred and twenty-seven unresectable large HCC patients receiving drug-eluting bead transarterial chemoembolization (DEB-TACE) treatment with CalliSpheres or HepaSpheres microspheres were analyzed. Treatment response, Karnofsky performance status (KPS) score, adverse events, main liver function indexes, time to progression (TTP), and overall survival (OS) were analyzed. Objective response rate (82.7% vs. 63.8%, p¼.030) and disease control rate (100.0% vs. 91.5%, p¼.030) were increased in CalliSpheres group compared to HepaSpheres group at 1 month after treatment, while no difference was found between the two groups regarding treatment response at 3 or 6 months post treatment (all p>.05). The KPS score at 1, 3, and 6 months was similar between the two groups (all p>.05). As for the liver function, the ALT, AST, ALB, and TBIL levels at 7 and 30 days were of no difference between the two groups (all p>.05). In addition, the adverse events including nausea/vomiting, pain, fever, myelosuppression, biloma, and abscess were of no difference between the two groups, either (all p>.05). In terms of survival profile, there was no difference regarding TTP (6.3 months (95%CI: 5.9-6.6 months) vs. 6.0 months (95%CI: 5.6-6.4 months), p¼.082) or OS (23.0 months (95%CI: 20.1-25.9 months) vs. 22.0 months (95%CI: 20.2-23.8 months), p¼.571) between the two groups. In conclusion, CalliSpheres seems to be superior in short-term efficacy and equal in long-term efficacy as well as safety compared to HepaSpheres for DEB-TACE treatment in unresectable large HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Besides, they also observed some fractured HepaSphere microspheres after drug release [83]. In short, the HepaSphere microspheres are also an appropriate option in DEB-TACE for HCC, showing favorable safety and efficacy [84,85]. In addition, other DEBs based on swelling mechanisms have also been developed, such as gelatin [86], poly (lacticco-glycolic acid) (PLGA) [87] and alginate [88] based polymeric hydrogels microspheres [89].…”

Section: Drug-eluting Beads Based On Swelling Mechanismmentioning

confidence: 99%

“…Besides, they also observed some fractured HepaSphere microspheres after drug release 83 . In short, the HepaSphere microspheres are also an appropriate option in DEB-TACE for HCC, showing favorable safety and efficacy 84 , 85 .…”

Section: Micro/nano Materials Used For Particulate Embolic Agentsmentioning

confidence: 99%

Bench-to-bedside development of multifunctional flexible embolic agents

Wang¹,

Rao²

2023

Theranostics

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) has been demonstrated to provide a survival benefit for patients with unresectable hepatocellular carcinoma (HCC). However, conventional TACE still faces limitations associated with complications, side effects, unsatisfactory tumor responses, repeated treatment, and narrow indications. For further improvement of TACE, additional beneficial functions such as degradability, drug-loading and releasing properties, detectability, targetability, and multiple therapeutic modalities were introduced. The purpose here is to provide a comprehensive overview of current and emerging particulate embolization technology with respect to materials. Therefore, this review systematically identified and described typical features, various functions, and practical applications of recently emerging micro/nano materials as particulate embolic agents for TACE. Besides, new insights into the liquid metals-based multifunctional and flexible embolic agents were highlighted. The current development routes and future outlooks of these micro/nano embolic materials were also presented to promote advancement in the field.

show abstract

Efficacy of transarterial chemoembolization treatment with 30–60-μm microspheres in patients with hepatocellular carcinoma

Tonkaz,

Nas,

Erkal Tonkaz

et al. 2024

Radiologie

View full text Add to dashboard Cite

Safety and efficacy of HepaSphere 50–100 μm in the treatment of hepatocellular carcinoma

Abstract: HepaSphere chemoembolization yielded a substantial objective response rate with an acceptable toxicity profile and should be considered an option for HCC treatment.

Cited by 7 publications

References 21 publications

Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients

Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients

Bench-to-bedside development of multifunctional flexible embolic agents

Efficacy of transarterial chemoembolization treatment with 30–60-μm microspheres in patients with hepatocellular carcinoma

Contact Info

Product

Resources

About